Cargando…

AZD7442 utilization for Pre-Exposure Prophylaxis Against COVID-19 in a French Early Access Program

BACKGROUND: AZD7442, a combination of 2 neutralizing antibodies, has been shown to reduce symptomatic COVID-19 risk by 83% at 6 months among high-risk individuals in a Phase 3 trial (PROVENT). The French Health Authorities authorized AZD7442 use in immunocompromised patients through Early Access Pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Artaud, C, Majed, L, Fabry-Vendrand, C, Taylor, S, Ferreira, C, Dube, S, Thabut, G, Suau, D, Lahouegue, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Poster Walks
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595782/ http://dx.doi.org/10.1093/eurpub/ckad160.977

Ejemplares similares

Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort
por: Aubier, Michel, et al.
Publicado: (2018)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
por: Sutton, K, et al.
Publicado: (2022)

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation
por: de Lamballerie, Xavier, et al.
Publicado: (2023)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
por: Levin, Myron J, et al.
Publicado: (2021)

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
por: Brady, Tyler, et al.
Publicado: (2022)

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
por: Benjamini, Ohad, et al.
Publicado: (2022)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
por: Laracy, Justin C., et al.
Publicado: (2023)

SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience
por: Pulvirenti, Federica, et al.
Publicado: (2023)

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Access and utilization of health services improved by trained posyandu cadres in rural Indonesia
por: Yani, F, et al.
Publicado: (2023)

Associations between retail food environment and organic food purchases in French households
por: Mejean, C, et al.
Publicado: (2023)

2733. Evusheld (AZD7442) Uptake and COVID-19 Outcomes in Solid Organ Transplant Recipients: A Secondary Analysis
por: Hayek, Haya, et al.
Publicado: (2023)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

Risk factors associated with depression among French university students during covid-19 lockdown
por: Sabatier, T, et al.
Publicado: (2022)

1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

Assessment of the impact of the Belgian and French food industry on obesity and population nutrition
por: Van Dam, I, et al.
Publicado: (2022)

Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
por: Chang, Andres, et al.
Publicado: (2023)

Fifty shades of food colours – Associations with cancer risk in a French cohort
por: Srour, B, et al.
Publicado: (2023)

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
por: Case, James Brett, et al.
Publicado: (2022)

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

Noise at school: any implications for teachers’ health? Findings from the French CONSTANCES study
por: Temam, S, et al.
Publicado: (2023)

Accessing health and health behaviour interventions by people with severe and multiple disadvantage
por: Jain, N, et al.
Publicado: (2023)

Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study
por: Portel, Laurent, et al.
Publicado: (2023)

Community Perceptions of Facilitators and Barriers to Post Natal Care access in Rural Laos
por: Mayangitan, JC, et al.
Publicado: (2022)

394. Consistency of AZD7442 (Cilgavimab/Tixagevimab) Pharmacokinetics Across Prophylaxis and Treatment and Adult and Pediatric Participants: Application of Population Pharmacokinetics to Enable Rapid Decision-Making During the COVID-19 Pandemic
por: Clegg, Lindsay E, et al.
Publicado: (2023)

Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
por: Jondreville, Ludovic, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
por: Tuffy, Kevin M, et al.
Publicado: (2023)

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

Inequalities in accessing COVID-19 healthcare for migrants and ethnic minorities: a systematic review
por: Bellini, A, et al.
Publicado: (2023)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
por: Hobbs, F. D. Richard, et al.
Publicado: (2023)

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

Open access as an intervention to improve outpatient waiting list
por: Zotti, N, et al.
Publicado: (2023)

Roadmap for implementation of genomics in healthcare: towards equity in access to genomics
por: Lopes, F, et al.
Publicado: (2023)

The Italian Roma, Sinti and Travellers Health Project for equity in access to care
por: Diodati, A, et al.
Publicado: (2022)

The association of loneliness and social isolation with healthcare utilization in Denmark
por: Christensen, J, et al.
Publicado: (2022)

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
por: Richard Hobbs, F D, et al.
Publicado: (2023)

Assessing examination equipment accessibility for the disabled using non-fidelity of checkup items
por: Park, B, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1iuoavoh47htcninl486pp6hf3